Literature DB >> 24920524

Combined use of crystalline sodium salt and polymeric precipitation inhibitors to improve pharmacokinetic profile of ibuprofen through supersaturation.

Jenna L Terebetski1, John J Cummings, Scott E Fauty, Bozena Michniak-Kohn.   

Abstract

To maximize the pharmacological effect of a pain reliever such as ibuprofen, early onset of action is critical. Unfortunately, the acidic nature of ibuprofen minimizes the amount of drug that can be solubilized under gastric conditions and would be available for immediate absorption upon entry into the intestine. Although the sodium salt of ibuprofen has higher solubility, rapid conversion from the salt to the poorly soluble free acid phase occurs under gastric conditions. Therefore, the combination of the highly soluble sodium salt form of ibuprofen with polymers was evaluated as an approach to prolong supersaturation of ibuprofen during the disproportionation of the salt. Binary combinations of ibuprofen sodium with polymers resulted in the identification of several formulations that demonstrated high degrees and extended durations of supersaturation during in vitro dissolution experiments. These formulations included HPMC, polyvinyl pyrrolidone-vinyl acetate copolymer (PVP-VA64), methylcellulose (MC), and hydroxypropyl cellulose (HPC). The in vitro supersaturation observed with these ibuprofen-polymer formulations translated to an increase in Cmax and an earlier Tmax for the PVP-VA64, MC, and HPC formulations relative to ibuprofen only controls when administered orally to rats under fasted conditions. Based on these observations, combining ibuprofen sodium with polymers such as PVP-VA64, MC, or HPC is a viable formulation approach to prolong supersaturation in the stomach and enable an optimized pharmacokinetic profile in vivo where rapid onset of action is desired.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24920524      PMCID: PMC4179647          DOI: 10.1208/s12249-014-0163-2

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  26 in total

Review 1.  Significance of controlling crystallization mechanisms and kinetics in pharmaceutical systems.

Authors:  N Rodríguez-Hornedo; D Murphy
Journal:  J Pharm Sci       Date:  1999-07       Impact factor: 3.534

Review 2.  Extended-release oral drug delivery technologies: monolithic matrix systems.

Authors:  Sandip B Tiwari; Ali R Rajabi-Siahboomi
Journal:  Methods Mol Biol       Date:  2008

Review 3.  Drug precipitation inhibitors in supersaturable formulations.

Authors:  Sen Xu; Wei-Guo Dai
Journal:  Int J Pharm       Date:  2013-05-13       Impact factor: 5.875

4.  Biowaiver monographs for immediate release solid oral dosage forms: ibuprofen.

Authors:  H Potthast; J B Dressman; H E Junginger; K K Midha; H Oeser; V P Shah; H Vogelpoel; D M Barends
Journal:  J Pharm Sci       Date:  2005-10       Impact factor: 3.534

5.  Pharmaceutical salts.

Authors:  S M Berge; L D Bighley; D C Monkhouse
Journal:  J Pharm Sci       Date:  1977-01       Impact factor: 3.534

6.  Inhibition of gastric emptying and secretion by pirenzepine and atropine in rats.

Authors:  C Scarpignato; M G Girone; F Tirelli; G Bertaccini
Journal:  Eur J Pharmacol       Date:  1984-06-01       Impact factor: 4.432

7.  Amphiphilic association of ibuprofen and two nonionic cellulose derivatives in aqueous solution.

Authors:  A Ridell; H Evertsson; S Nilsson; L O Sundelöf
Journal:  J Pharm Sci       Date:  1999-11       Impact factor: 3.534

8.  Crystallization of hydrocortisone acetate: influence of polymers.

Authors:  S L Raghavan; A Trividic; A F Davis; J Hadgraft
Journal:  Int J Pharm       Date:  2001-01-16       Impact factor: 5.875

Review 9.  Salt formation to improve drug solubility.

Authors:  Abu T M Serajuddin
Journal:  Adv Drug Deliv Rev       Date:  2007-05-29       Impact factor: 15.470

10.  Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations.

Authors:  Héctor R Guzmán; Mark Tawa; Zhong Zhang; Pasut Ratanabanangkoon; Paul Shaw; Colin R Gardner; Hongming Chen; Jean-Pierre Moreau; Orn Almarsson; Julius F Remenar
Journal:  J Pharm Sci       Date:  2007-10       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.